# Commitments Concrete work tasks, follow-ups, approvals, and scheduled items extracted from Gmail, Notion, Slack, direct mentions, and other work-relevant sources. Personal errands and life admin live in `/personal-logistics.md` instead. ## Active ### china-cde-cell-gene-therapy-rules-2026: verify CDE classification scope for Chinese pharma / CDMO conversations - Owner: me - Source: web-search — cisema.com 2026-07-24 (China CDE Defines Classification Rules for Cell & Gene Therapy Drugs) - Due: unscheduled - Status: open - Notes: Single credible regulatory-trade source. Pull the NMPA/CDE-direct release before the next vendor sync; check whether any active CellShot-TriArm or ClinoReactor-class deals depend on the new classification scope. ### celvivo-clinoreactor-thewell-bioscience-xeno-free: verify TheWell Bioscience co-marketing signal on next CelVivo check - Owner: me - Source: web-search — thewellbio.com 2026-07-21 / 2026-07-23 / 2026-07-25 (Xeno-Free Cell Culture Media, Stem Cell Culture Product Guide, Apical-Out Organoids white paper — all explicitly name "CelVivo ClinoReactor™") - Due: unscheduled - Status: open - Notes: First vendor-anchored CelVivo ClinoReactor signal in any Tavily pull (prior pulls returned only MO:BOT / generic organoid). TheWell Bioscience is a hydrogel-media partner; their workflow pages position ClinoReactor as the scale-up vessel for apical-out organoids + hMSC expansion. Confirm with CelVivo whether this is a sanctioned co-marketing arrangement and whether it maps to any active Chinese pharma / CDMO deal. ## Completed recently